JSJCX | NRGEX | JSJCX / NRGEX | |
Total Expense Ratio | 1.95 | 0.03 | 6,500% |
Annual Report Gross Expense Ratio | 2.10 | 0.69 | 304% |
Fund Existence | 8 years | 4 years | - |
Gain YTD | 5.045 | -3.342 | -151% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 541M | 8.69B | 6% |
Annual Yield % from dividends | 2.41 | 0.54 | 447% |
Returns for 1 year | -1.58 | -9.46 | 17% |
Returns for 3 years | 27.73 | 8.17 | 339% |
Returns for 5 years | -18.89 | N/A | - |
Returns for 10 years | N/A | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
JFNNX | 75.60 | 0.47 | +0.63% |
Janus Henderson Global Life Sciences N | |||
GMCUX | 16.77 | 0.04 | +0.24% |
Goldman Sachs Small/Mid Cap Equity R6 | |||
RLEFX | 38.98 | 0.04 | +0.10% |
American Funds American Balanced R5E | |||
SGQIX | 46.28 | -0.03 | -0.06% |
DWS International Growth Inst | |||
TAISX | 13.83 | -0.09 | -0.65% |
Nuveen Quant Intl Small Cap Eq I |